ARCHIVES

DeVita Resigns As No. 2 At Sloan-Kettering To “Pursue Clinical Research,” Hospital Says

This article is from The Cancer Letter archive.

Vol. 17 No. 22 | May 31, 1991

Download PDF Visit The Full Archive

Related Articles

Afinitor Increases Overall Survival To 3.5 Years in Phase III Trial

September 26, 2014

White House Backs Down FY 86 Cuts, Says Now They Will Be Limited To Trimming Indirect Costs

January 10, 1986

Hong Succeeds Curran As AACR President, Horwitz Is President-Elect; 5 New Directors.

March 30, 2001

Univ. Of Pittsburgh Seeks Senior Prevention Trial Of Tamoxifin should Resume

June 17, 1994

NRSAs Renamed For Kirschstein.

June 21, 2002

Panel Recommends Peer Review “Fine Tuning” Changes Including Mandatory Service By All NIH Grantees

January 6, 1984